Sun Pharma Rolls Out Budget-Friendly Semaglutide Duo in India 

Key Highlights: 

• Sun has launched its semaglutide injection in India under two brands: Noveltreat and Sematrinity, making all dose strengths available across indications. Noveltreat is approved for chronic weight management in adults alongside diet and exercise, while Sematrinity targets adults with inadequately controlled type 2 diabetes as an adjunct to lifestyle changes 

• The company is offering a broad dosing range to support treatment flexibility, with Noveltreat available in five strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg) and Sematrinity in two strengths (2 mg/1.5 mL and 4 mg/3 mL). Notably, Sun Pharma has priced both therapies significantly lower than innovator brands, with weekly costs ranging ~₹900–₹2,000 for Noveltreat and ~₹750–₹1,300 for Sematrinity, aiming to improve patient access and affordability in India 

• Building on its expertise in complex drug manufacturing, Sun Pharma is also rolling out a holistic patient support program to guide patients throughout therapy. The company has paired this with user-friendly delivery devices, Noveltreat features a concealed-needle prefilled pen to reduce injection anxiety, while Sematrinity comes in a multi-dose pen with a smooth dialer for accurate dosing, with both pens developed by global device suppliers and manufactured in Europe  

Implications: 

By launching semaglutide under two differentiated brands with full dose coverage and price points 60%+ below innovator levels, Sun is set to rapidly expand access in both obesity and type 2 diabetes, accelerating GLP‑1 class penetration beyond top-tier metros. 
The combination of European-made pens, device features tailored to injection comfort, and a structured patient support program should support persistence and physician confidence, strengthening Sun’s positioning against other Indian GLP‑1 entrants as a high‑volume, value‑plus‑quality player.  

Source: Sun Pharma | Image: Sun Pharma